AF
TVTX icon

Allworth Financial’s Travere Therapeutics TVTX Stock Holding History

Allworth Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9K Sell
806
-1,415
-64% -$42.3K ﹤0.01% 2859
2025
Q4 		$84.9K Buy
2,221
+1,569
+241% +$51K ﹤0.01% 1853
2025
Q3 		$15.6K Buy
652
+252
+63% +$4.74K ﹤0.01% 2855
2025
Q2 		$5.92K Sell
400
-26
-6% -$431 ﹤0.01% 3174
2025
Q1 		$7.51K Sell
426
-46
-10% -$934 ﹤0.01% 2557
2024
Q4 		$9.19K Sell
472
-96
-17% -$1.7K ﹤0.01% 2473
2024
Q3 		$7.95K Hold
568
– – ﹤0.01% 2368
2024
Q2 		$5.57K Buy
+568
New +$3.83K ﹤0.01% 2476
2023
Q4 		– Sell
-48
Closed -$430 – 3625
2023
Q3 		$430 Buy
48
+29
+153% +$409 ﹤0.01% 3075
2023
Q2 		$292 Sell
19
-23
-55% -$418 ﹤0.01% 3025
2023
Q1 		$945 Buy
+42
New +$893 ﹤0.01% 2692
2022
Q4 		– Sell
-50
Closed -$1K – 3201
2022
Q3 		$1K Buy
50
+33
+194% +$853 ﹤0.01% 2523
2022
Q2 		$0 Buy
+17
New +$428 ﹤0.01% 2824

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allworth Financial's TVTX Position: Q1 2026 in Review

Allworth Financial reduced its Travere Therapeutics (TVTX) stake by 64% in Q1 2026, selling an estimated $42.3K and leaving 806 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

Allworth Financial first reported a position in TVTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $84.9K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Allworth Financial held 806 shares of Travere Therapeutics worth $23.9K as of Q1 2026.
  • Allworth Financial sold 1,415 Travere Therapeutics shares in Q1 2026, an estimated $42.3K.
  • Travere Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #2859 holding.
  • Allworth Financial first reported a position in Travere Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Allworth Financial's Travere Therapeutics position peaked at $84.9K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.